Grifols said the layoffs sparked by its restructuring represent just 8% of its workforce. But the cuts will happen mainly in the Barcelona-based company’s U.S. plasma operations, source of most of the plasma that is the basis for its biologic medicines.
SpliceBio will use its €50 million in financing to advance development of a gene therapy for Stargardt disease, a rare eye disorder. The biotech’s technology enables the delivery of genes that are too large for the capacity of the adeno-associated viruses widely used in the delivery of genetic medicines.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Neuroelectrics is planning a pivotal test of its wearable medical device, which delivers brain electrical stimulation to treat epilepsy. The startup's Series A round of funding was led by Morningside Ventures.
Grifols's acquisition of GigaGen comes as the startup's Covid-19 antibody drug is set to start Phase 1 testing. Barcelona-based Grifols says GigaGen’s technology could also help it expand to engineered antibody therapies.
The biotech company presented data for AMG 510 at the European Society for Medical Oncology during the weekend. Although the drug showed activity, the data got mixed reactions from investment bank analysts.
The company announced the presentation of data at the ESMO meeting in Barcelona for Tibsovo, in patients with IDH1-mutant bile duct cancer. The drug is approved for treating IDH1-mutation positive acute myeloid leukemia.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Data for AstraZeneca's Imfinzi showed an improvement in overall survival and duration of response in patients with first-line extensive-stage small-cell lung cancer. Roche's Tecentriq already has approval in that indication.
Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose.
Analysts nevertheless wrote that with each data update, Lilly's RET inhibitor LOXO-292 (selpercatinib) appears less differentiated on efficacy as well as tolerability from Blueprint Medicines' BLU-667 (pralsetinib).
Several patients in the trial of CYAD-101 combined with chemotherapy responded to treatment, but both a company executive and a gastrointestinal cancer expert cautioned the data were too preliminary to draw conclusions.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Nearly a year after its acquisition of Withings, Nokia highlighted product development news for digital health devices.
See the best and worst from Mobile World Congress, plus new Microsoft security features and thoughts on the Apple encryption battle.
At first I thought I was listening to Nine Inch Nails. That’s when I looked up and saw the crazy dancers, toddlers walking together and a businessman surfing. The minute-long cascade of images could be mistaken for the latest Obamacare marketing appeal to millennials. Instead, it signals the launch of Denmark-based Agnitio’s closed-loop marketing platform […]
Grifols‘ (MCE:GRF) $4 billion acquisition of Talecris Biotherapeutics (NASDAQ:TLCR) now has the regulatory clearance to close. Barcelona, Spain-based Grifols said Wednesday that the U.S. Federal Trade Commission has accepted a consent agreement that outlines the conditions for merger of the blood therapeutics companies. Last month, the FTC and the companies reached a preliminary agreement that […]